LAUSR

Targeted therapy and PD - 1/L1 inhibitors are the main treat - ments for BRAF V600 - mutated melanomas [ 1,2 ] . Recently, PD - 1 inhibitors for melanoma with toripalimab have been developed [ 3 ] , and vemurafenib is a synthetic oral BRAF inhibitor. Previously, skin toxicity appeared to be more severe in patients receiving vemurafenib following anti - PD - 1 therapy [ 4,5 ] . Here we describe a rare and severe cumulative dermatologic toxicity ( grade 4 ) that developed in a patient with metastatic cutaneous melanoma during toripalimab combined with vemurafenib following toripa - limab alone. A 52 - year - old Chinese woman with